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Introduction
Several high-income countries, includ-
ing the United Kingdom, are tackling
‘‘health inequalities’’ [1]. In 2009, the
various UK governments announced
large-scale programmes to screen and
treat cardiovascular risk [2]. The respec-
tive health ministers stated that the
programmes would reduce health inequal-
ities, although opposition parties generally
predicted the opposite [3]. The potential
effects of any screening policy on health
inequalities clearly need to be urgently
considered, not least in order to inform
current policy development in the UK
[4,5] and internationally [6].
The primary prevention of cardiovas-
cular disease (CVD) is dependent on the
effective reduction of the major risk
factors, particularly by reducing tobacco
use and adopting a healthier diet [2].
However, the substantial excess burden of
morbidity and mortality due to CVD in
disadvantaged groups raises major chal-
lenges. Social gradients in the major
cardiovascular risk factors can explain
approximately three-quarters of this excess
burden; smoking alone can explain more
than half [7,8].
Assessing the potential effect of risk
factor reductions on socioeconomic in-
equalities in health is crucial. McLaren et
al. usefully distinguish between ‘‘agentic’’
prevention strategies (which rely solely on
individuals making and sustaining behav-
iour change) and ‘‘structural’’ strategies
(which work through changes in the wider
social environment [9]. There is increasing
evidence to suggest that addressing CVD
risk factors using ‘‘structural’’ whole-pop-
ulation approaches generally reduces so-
cial inequalities. There is also worrying
preliminary evidence that screening and
treating high-risk individuals (‘‘agentic’’
strategies) might increase the inequalities
gap. In this Policy Forum article, we
review this evidence, and consider differ-
ent potential approaches for reducing
inequalities.
The Whole-Population
Approach for Preventing CVD
Some two decades ago, Geoffrey Rose
suggested that a small reduction in risk in a
large number of people may prevent many
more cases than treating a small number
at higher risk [10]. He therefore cautioned
against simply pursuing individual-level
interventions targeted at changing risk
profiles in this latter group. Rose instead
advocated a dual strategy, also using a
whole-population approach to change
everyone’s exposure. That approach
would support policies that work directly
on what Rose called ‘‘the underlying
causes of disease’’; for example, via
statutory regulation and environmental
controls, rather than indirectly by chang-
ing risk factors on a person-by-person
basis. Whole-population interventions can
indeed reduce risk factors across entire
countries. National legislation and fiscal
policies can be both effective and cost-
saving, whether banning industrial trans-
fats (Denmark), halving dietary salt in
processed foods (Finland), or promoting
smoke-free public spaces (Scotland, Ire-
land, Italy, and elsewhere) [11–14].
Growing international evidence now
supports the Rose hypothesis [15–17].
Small reductions in population cholesterol
concentrations, blood pressure, or smok-
ing then translate into substantial reduc-
tions in cardiovascular events and deaths
[17–19]. This evidence suggests that
comprehensive policies can be more
effective in reducing risk factors and
improving health than a high-risk individ-
ual approach. Furthermore, identifying
individuals with a threshold of a 20% 10-
year CVD event risk would then necessi-
tate multiple preventive treatments for
one-quarter of the population. In the
UK, this might decrease UK cardiovascu-
lar mortality by approximately 17% (as-
suming normal adherence). Conversely,
country-wide policies to reduce cholesterol
and smoking population levels by just 5%
would decrease UK mortality substantially
more, by about 26% [15]. Capewell et al.
reported similar findings for the US
population [18].
The Whole-Population
Approach for Reducing Social
Inequalities in CVD
There is increasing evidence to support
health equity strategies that take a whole-
population approach to CVD risk factors.
This includes simply considering arithmet-
ical principles. Disadvantaged groups experience
a greater CVD burden. They are thus likely to gain
extra benefit if a risk factor is uniformly reduced
across the entire population, with a consequent
reduction in absolute (but not necessarily relative)
inequalities. This simple arithmetic was spelt
out by Diederichsen and colleagues [20].
More recent support came from Kivi-
maki et al., who quantified the 15-year
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ly across a male population (reductions of
10 mmHg in blood pressure, 2 mmol/l in
total cholesterol, and 1 mmol/l in glucose)
[21]. Although relative inequalities would
remain, such interventions might reduce
the absolute mortality gap between rich
and poor by approximately 70% [21].
Smoking rates and exposure to environ-
mental tobacco smoke are higher in
poorer groups in Scotland, which is
consistent with other high-income coun-
tries [22]. However, following the Scottish
smoke-free legislation in 2006, there was a
substantial fall in hospital admissions for
heart attack and ‘‘acute coronary syn-
drome’’ (involving a 14% reduction in
smokers and a 21% fall in never smokers).
This drop was uniform across social
groups [13].
Strong regulatory policies, particularly
those including increases in cigarette price,
are also associated with declines in tobacco
use of a similar magnitude across socio-
economic groups [23]. This suggests that,
in the many countries where smoking rates
are higher in poorer groups, the absolute
benefit will be greater than in affluent
groups. Indeed, men and women in lower
socioeconomic groups appear more re-
sponsive to uniform increases in cigarette
price than affluent groups [24,25]. How-
ever, attention needs to be paid to how
inequalities within disadvantaged groups
can influence responses to population-
wide interventions and their overall im-
pacts [26].
Social differences are observed in diet,
as in smoking. Thus, low-income families
consume more saturated fat and fewer
fruits and vegetables than more affluent
families [27]. Strong supporting evidence
for the effectiveness of a population-wide
diet intervention comes from the United
States. Folic acid fortification of cereals
was introduced in 1996. Absolute social
differences in blood folate levels were
subsequently reduced by 67% [28]. Fur-
thermore, comparable reductions in in-
equalities in dental caries followed water
fluoridation [29]. The implications are
clear. Eradication of dietary transfats, or
halving the salt content of bread, would
disproportionately benefit deprived groups.
Of course, the population approach is
unlikely to totally abolish inequalities since
many of the drivers of disadvantage lie
even further upstream. For instance,
structural interventions in the Ontario
Smoke Free Strategy included smoking
bans in enclosed public places and en-
closed work places, laws on tobacco sales
to minors, and restrictions on the display
of tobacco products in retail outlets.
Overall smoking rates in the province fell.
However, 40% of aboriginal women and
men are still smoking, as are 34% of adults
with less than a secondary school educa-
tion compared to 11% who had a
bachelor’s degree or higher [30].
The population approach has a strong
ethical base. It is in step with the
‘‘stewardship’’ model of public health that
places obligations on governments to
enable conditions in which everyone can
lead a healthy life [31]. Classic examples
include legislating for clean drinking
water, seatbelts, and food hygiene. Such
principles have long underpinned broader
policies to protect well-being, by regulat-
ing market economies and providing for
basic needs [32]. There is also some
support from the political right under the
banner of ‘‘libertarian paternalism’’ or
‘‘nudge’’ (routinely presenting options to
increase the likelihood that people will
choose what they would on reflection most
prefer) [33].
However, population-based structural
approaches to reduce inequalities might
be difficult to achieve. Such approaches
ideally require concerted cross-sectoral
efforts such as universal access to healthy
food, reductions in work place stress, and
access to safe environments for physical
activity for all [32].
The High-Risk Approach for
Preventing CVD
In the UK, the high-risk approach for
preventing CVD is typified by the health
checksprogrammePuttingPreventionFirst,
implemented in England [2]. All adults
aged 40–74 years will be invited to be
screened for CVD risk. Individuals found to
exceed a 20% risk of a cardiovascular event
in the next 10 years will be treated with a
combination of lifestyle advice plus tablets
to reduce blood cholesterol and blood
pressure, as appropriate [2].
This is a controversial area. Manuel et
al. recently ‘‘revisited’’ Rose [34]. Their
influential article advocated the high-risk
approach [34]. However, their methodol-
ogy and conclusions were subsequently
criticised by Whincup and others [35].
The methodological limitations identified
by these critics meant that firstly, the
Manuel analysis systematically over-esti-
mated the likely benefit of individual
strategies (by including patients with
established CVD, inflating the numbers
in the ‘‘high-risk’’ group, assuming that
effectiveness in routine clinical practice
equalled efficacy in RCTs, and ignoring
under-treatment and poor long-term ad-
herence). Secondly, they systematically
under-estimated the contribution of pop-
ulation strategies (by conservatively assum-
ing a 2% reduction in population choles-
terol when falls of 10%–18% have been
observed elsewhere, and by using an
unvalidated model and also failing to
mention that population approaches to
prevention also reduce the pool of high-
risk people requiring drug treatment) [35].
Likewise, Zulman et al. recently pre-
ferred a high-intensity treatment interven-
tion in the US adult population [36].
However, their mortality estimates were 3-
fold higher than previous publications [36].
This over-estimate probably reflected suc-
cessive optimistic assumptions about effec-
tiveness and long-term adherence [36,37].
Furthermore, critics of the high-risk
cardiovascular risk screening approach
suggest that this strategy might have low
Summary Points
N The primary prevention of cardiovascular disease (CVD) is dependent on the
effective reduction of the major risk factors for CVD, particularly tobacco control
and a healthier diet.
N The high-risk approach to prevent CVD typically involves population screening.
Those exceeding a risk threshold are then given lifestyle advice and/or tablets
to reduce blood cholesterol and blood pressure.
N Evidence suggests this high-risk approach typically widens socioeconomic
inequalities. Such inequalities have been reported in screening, healthy diet
advice, smoking cessation, statin and anti-hypertensive prescribing, and
adherence.
N The alternative approach is population-wide CVD prevention. For example,
legislating for smoke-free public spaces, banning dietary transfats, or halving
daily dietary salt intake. Such strategies are generally effective and cost-saving;
there is also increasing evidence that they can reduce health inequalities.
N We conclude that screening and treating high-risk individuals represents a
relatively ineffective CVD prevention approach that typically widens social
inequalities.
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risk, and achieve a small population
impact at high cost; as well as result in
the medicalisation of previously healthy
individuals. Furthermore, it does not
address the root causes of the problem
[38–40]. Equally seriously, this high-risk
approach will almost certainly widen
inequalities.
The High-Risk Approach May
Worsen Social Inequalities in
CVD
There is increasing evidence that in-
equalities in risk factors can widen when
effects are mediated through individual-
level changes in knowledge, motivation,
and behaviour (for example, national
health promotion campaigns and behav-
ioural change programmes) [41,42]. Fur-
thermore, because such interventions do
not work directly on population exposure
to risk factors, they do not address
inequalities in risk-factor profiles in subse-
quent cohorts.
‘‘Agentic’’ interventions, which require
mobilisation of an individual’s resources,
whether material or psychological, gener-
ally favour those with more resources, thus
tending to increase social inequalities
[9,41,42]. This parallels what Tudor Hart
memorably described as the ‘‘Inverse Care
Law’’—the availability of good medical
care tends to vary inversely with the need
for it in the population served [43]. Thus,
the people in the poorest health gain the
lowest net health benefit from the inter-
ventions [43]. Disadvantage can occur at
every stage in the process, from the
person’s beliefs about health and disease,
and actual health behaviour, to presenta-
tion, screening, risk assessment, negotia-
tion, participation, programme persis-
tence, and treatment adherence. Tugwell
et al. usefully described this cumulative
inequality as the ‘‘staircase effect’’ [44].
Inequalities have also been reported in
the screening and detection of cancer as
well as CVD. For instance, women who
choose to attend the National Health
Service (NHS) Breast Screening Pro-
gramme come more from affluent areas
[45].
In the US, Frohlich’s analysis likewise
suggested that even when individual-based
interventions are widely applied (such as
screening or health information cam-
paigns), they may increase disparities
[46]. Furthermore, examples of the inverse
care law in CVD primary prevention
prescribing have also been reported.
Substantial socioeconomic gradients exist
in statin use, both in the UK and in the
Danish health care system, which aims,
like the NHS, to ensure equity in medical
care [47–49].
Likewise, inequalities in anti-hyperten-
sive therapy have been reported. A recent
study suggested that social and ethnic
disparities in the detection and manage-
ment of hypertension have persisted in the
UK despite major investment in quality
improvement initiatives, including pay for
performance [50]. Long-term adherence
(compliance) with primary prevention
medications barely reaches 50%, and is
often worse in more deprived groups [51–
53]. Furthermore, inequalities in adher-
ence have been specifically reported for
both statins and anti-hypertensive medi-
cations [54,55].
For smoking cessation, greater use and
higher quit rates of cessation services by
more advantaged individuals are a real
concern [56]. Affluent smokers tend to
receive more help, and are more likely to
quit [57,58]. Increasing quit rates in more
affluent smokers were also recently report-
ed in Inter99, the Danish trail of primary
prevention in general practice [59]. Sim-
ilar inequalities have also been reported in
workplace smoking interventions [57].
With respect to dietary advice, US
policies traditionally favour individual
approaches over public health strategies.
There, Kanjilal and colleagues recently
reported bigger declines in CVD risk
factors in more affluent groups [60].
Supporting evidence comes from a recent
systematic review of nutritional interven-
tions in individuals and groups [61]. In
schools, fruit and vegetable consumption
typically increased more in affluent fami-
lies; interventions were correspondingly
less effective in disadvantaged areas.
Likewise, in a US primary care setting,
interventions to reduce fat intake were less
successful in blacks than in (more affluent)
whites [61]. In Germany, the Cardiovas-
cular Prevention Study compared three
strategies involving advice from profes-
sionals and media. After 7 years, hyper-
cholesterolaemia improved only in upper
social groups, thereby increasing the gap
between the health of rich and poor [62].
In England, a high-risk approach to
CVD prevention that specifically priori-
tises disadvantaged groups and localities is
being actively promoted. The National
Institute for Health and Clinical Excel-
lence recently published public health
guidelines advising specific approaches
for identifying and supporting people most
at risk of dying prematurely [63]. Else-
where, more innovative strategies are
being developed for poor communities—
for example, use of non-physician health
care workers, financial incentives, and
availability of low-cost generic ‘‘polypills’’
[64,65]. Evidence to confirm the effective-
ness and cost-effectiveness of such targeted
strategies in reducing health inequalities is





Might a coordinated approach that
integrates population-based and high-risk
approaches be more effective? The Norsjo
Community Intervention Program in Swe-
den is an example of a model that
combines population health and health
sector interventions. The program created
a local health promotion collaboration
between healthcare providers, grocery
stores, schools, and municipal authorities.
Primary care physicians contacted patients
for systematic risk factor screening and
counselling aimed at CVD risk reduction.
Community interventions included chang-
es in food labelling to make it easier to
adhere to dietary recommendations. The
predicted CVD mortality risk was reduced
by 36% in the intervention area compared
to 1% in a control community. Socioeco-
nomically less privileged groups benefited




ulations are susceptible to under-diagnosis
of hypertension, diabetes, and hypercho-
lesterolemia and also to suboptimal care
for interventions to reduce risk. Risk factor
modification through tailored interven-
tions in high-risk groups might therefore
produce considerable benefits; however,
evaluation is urgently required.
Conclusions
Given the ubiquity of social and health
inequalities, we should not be surprised if
interventions to reduce CVD have differ-
ential effects, with advantaged groups
deriving greater benefit than poorer
groups. We have suggested that the
potential for such unequal effects is greater
for high-risk approaches, where change is
contingent on action by individual patients
and healthcare providers, compared with
whole population approaches, where
change is societal and instituted collective-
ly by agencies with statutory responsibility
for public health.
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service, the population approach offers
governments the opportunity to act direct-
ly on population exposure to risk factors. It
thus addresses the major drivers of health
and health inequalities [68]. Meanwhile,
evidence that healthcare interventions can
generate and compound risk-factor in-
equalities is steadily accumulating [42].
We therefore look forward to future
analyses from Tugwell and other col-
leagues in the Cochrane Health Equity
Field [44]. However, that is no excuse for
delay.
In conclusion, there is evidence that
CVD prevention strategies for screening
and treating high-risk individuals may
represent a relatively ineffective approach
that typically widens social inequalities. In
contrast, policy interventions to limit risk-
factor exposure across populations appear
cheaper and more effective; they could
also contribute to levelling health across
socioeconomic groups. The two approach-
es are complementary, and Rose’s advo-
cacy of a dual strategy may prove
prophetic [10]. However, all future strat-
egies aimed at improving population
health will merit rigorous evaluation of
their potential impact on inequities.
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